“Letermovir Prophylaxis Reduces Clinically Significant CMV Infections in High-Risk Pediatric Hematopoietic Stem Cell Transplant Recipients with Inborn Errors of Immunity”

https://pubmed.ncbi.nlm.nih.gov/38117473

CMV prophylaxis with letermovir in high-risk pediatric hematopoietic stem cell transplantation recipients with inborn errors of immunity showed reduced incidence of clinically significant CMV infections compared to a historical cohort.